Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Pearl Toh, 11 Jun 2019
The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.

Entecavir slightly better than lamivudine for patients with HBV-related AE, ACLF

08 Jul 2017

Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.

Researchers performed a comprehensive literature search of studies on therapy involving entecavir or lamivudine for chronic HBV-related acute exacerbation with or without ACLF published before December 2015.

Short- (within 4 months) and long-term (beyond 4 months) mortality were the main outcomes. The secondary outcomes were virological and biochemical responses, ACLF recurrence, and safety.

Three prospective and eight retrospective cohort studies met the inclusion criteria, involving a total of 1,491 patients. Overall, short- (risk ratio [RR], 0.99; 95 percent CI, 0.78 to 1.27) and long-term mortality rates (RR, 0.82; 0.45 to 1.52) were similar among all patients who received entecavir or lamivudine.

On the other hand, long-term outcome was more favourable in patients with ACLF who received entecavir vs lamivudine (RR, 0.60; 0.45 to 0.80). In addition, entecavir yielded more efficient virological and biochemical responses than did lamivudine with respect to the HBV DNA undetectable rate (RR, 1.34; 1.09 to 1.63), HBV DNA reduction rate (weighted mean difference, ‒0.41; ‒0.69 to ‒0.13) and serum alanine aminotransferase normalization rate (RR, 1.13; 1.05 to 1.21).

Additional larger, long-term randomized controlled trials are warranted to confirm these findings, according to researchers.

Oral nucleos(t)ide analogues are commonly given in patients with chronic HBV-related acute exacerbation and ACLF, researchers said. This study provided evidence to the safety and efficacy of entecavir and lamivudine to such patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Pearl Toh, 11 Jun 2019
The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.